A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

The Food and Drug Administration (FDA) has updated the labeling for Kisunla ™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer ...

Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance ...

A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

Cognition Therapeutics surges 35% after a positive FDA meeting for Alzheimer’s drug zervimesine. Read more here.

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

While the year started out as cautiously optimistic, stemming from the peak of biotech initial public offering (IPO) activity ...

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug.

Mitolyn is a natural weight loss supplement designed to target a hidden cause of stubborn fat—poor mitochondrial health. Based on Harvard research ...